Zepbound

Description

      Zepbound

• Medication Guide
• Instructions for Use – Pen
• Instructions for Use – Vial

Zepbound® (Tirzepatide) 

Zepbound® is a prescription medication containing the active ingredient tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This once-weekly injectable therapy is designed to support adults living with obesity or overweight conditions, particularly those with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidemia. By targeting two key metabolic pathways, Zepbound helps regulate blood sugar levels, enhances insulin sensitivity, and promotes significant body weight reduction.

Chemical Composition

• Active Ingredient: Tirzepatide

• Molecular Formula: C_40H_56N_10O_11

• Molecular Weight: 868.0 g/mol

• Tirzepatide is a synthetic peptide that mimics the natural incretin hormones GIP and GLP-1, stimulating insulin secretion in response to elevated blood glucose while reducing appetite and promoting satiety.

• Excipients: May include buffers, stabilizers, and solvents necessary for peptide stability in a prefilled injectable pen.

Usage & Benefits

• Zepbound is intended for once-weekly subcutaneous injection, usually in the abdomen, thigh, or upper arm.

• Helps achieve sustainable weight loss when used alongside a reduced-calorie diet and increased physical activity.

• Supports improved glycemic control in patients with obesity-related metabolic disorders.

• May help reduce cardiovascular risk factors through weight management and improved metabolic health.

Storage Instructions

• Store Zepbound pens in a refrigerator at 2–8°C (36–46°F) before first use.

• Do not freeze.

• Once in use, pens may be stored at room temperature (up to 30°C / 86°F) for up to 21 days.

• Keep the pen away from direct heat and light, and always store with the needle cap on to maintain sterility.

Precautions

• Only prescribed for adults; consult a healthcare provider for suitability.

• Regular monitoring of blood glucose and weight is recommended.

• Potential side effects may include nausea, vomiting, diarrhea, or injection site reactions.

Zepbound represents an innovative therapeutic option for adults struggling with obesity and related conditions, combining dual receptor agonist activity with convenient once-weekly administration to enhance adherence and clinical outcomes.